Moreover, a pre-clinical proteomic signature has been identified through analyzing serum samples from first-degree relatives of North American RA patients, further demonstrating that serum proteomic differences between those who progressed to RA and other high-risk individuals exist years before the disease onset, regardless of ACPA status (5). The gene discussed is PRTN3; the disease is rheumatoid arthritis.